FENNEC PHARMACEUTICALS INC (FENC)       9.97  +0.26 (+2.68%)

9.97  +0.26 (+2.68%)

CA31447P1009 - Common Stock - After market: 9.97 0 (0%)

FENNEC PHARMACEUTICALS INC9.97

NASDAQ:FENC (2/7/2023, 7:00:01 PM)+0.26 (+2.68%)

After market: 9.97 0 (0%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS Sector Health Care
GICS Industry Biotechnology

Chartmill FA Rating
Valuation Growth
Profitability Health
Dividend

Overview
Earnings (Last) 11-11 2022-11-11/bmo Earnings (Next) 02-27 2023-02-27/amc
Ins Owners 1.51% Inst Owners 43.3%
Market Cap 261.82M Shares 26.26M
PE N/A Fwd PE N/A
Dividend Yield N/A Analysts 83.33
IPO 06-05 2001-06-05

Stock Screener Links

Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

FENC Daily chart

Company Profile

Fennec Pharmaceuticals, Inc. operates as a biopharmaceutical company. The company is headquartered in Research Triangle Park, North Carolina and currently employs 10 full-time employees. The company went IPO on 2001-06-05. The firm is focused on the development of PEDMARK for the prevention of platinum-induced ototoxicity in pediatric cancer patients. The Company’s only product candidate in the clinical-stage of development is PEDMARK. The company announced two results of Phase III clinical trials for the prevention of cisplatin induced hearing loss, or ototoxicity in children, including the pivotal Phase III study SIOPEL 6 and the proof-of-concept Phase III study in collaboration with the Children’s Oncology Group (COG ACCL0431). PEDMARK has the potential to reduce the incidence and/or grade of chemotherapy-induced hearing loss. The Company’s four subsidiaries includes Oxiquant, Inc. and Fennec Pharmaceuticals, Inc., both Delaware corporations, Cadherin Biomedical Inc., a Canadian company, and Fennec Pharmaceuticals (EU) Limited (Fennec Limited), an Ireland company. Apart from Fennec Pharmaceuticals, Inc., all subsidiaries are inactive.

Company Info

FENNEC PHARMACEUTICALS INC

PO Box 13628, 68 Tw Alexander Dr

RESEARCH TRIANGLE PARK NORTH CAROLINA 27709

P: 19196364530.0

CEO: Rostislav Raykov

Employees: 10

Website: http://fennecpharma.com/

FENC News

News Image8 days ago - Seeking AlphaFENC stock gains on FDA orphan drug exclusivity for ear toxicity therapy (NASDAQ:FENC)

Fennec Pharma (FENC) announced Tuesday that the FDA granted the Orphan Drug Designation for its ear toxicity therapy Pedmark. Read the full story here.

News Image8 days ago - Fennec Pharmaceuticals Inc.Fennec Pharmaceuticals Announces PEDMARK® (sodium thiosulfate injection) Receives Orphan Drug Exclusivity from U.S. FDA

~ PEDMARK® is the First and Only FDA-Approved Therapy Indicated to Reduce the Risk of Ototoxicity Associated with Cisplatin in Pediatric Patients with...

News Image14 days ago - Seeking AlphaFENC stock gains as NCCN recommends ear toxicity therapy (NASDAQ:FENC)

Fennec Pharma (FENC) rose Wednesday morning after announcing that the National Comprehensive Cancer Network ((NCCN)) recommended its ear toxicity therapy Pedmark. Read the full story here.

News Image14 days ago - Fennec Pharmaceuticals Inc.Fennec Pharmaceuticals Announces Updated NCCN Clinical Practice Guidelines Recommend PEDMARK® (sodium thiosulfate injection) to Reduce the Risk of Cisplatin-Induced Hearing Loss in Pediatric Patients

~ PEDMARK is the First and Only FDA-Approved Therapy Indicated to Reduce the Risk of Ototoxicity Associated with Cisplatin in Pediatric Patients with...

News Image3 months ago - Fennec Pharmaceuticals Inc.Fennec Pharmaceuticals Announces Third Quarter 2022 Financial Results and Provides Business Update

~ In September 2022, FDA Approved PEDMARK®, the First and Only FDA-Approved Therapy Indicated to Reduce the Risk of Ototoxicity Associated with Cisplatin...

News Image4 months ago - Fennec Pharmaceuticals Inc.Fennec Pharmaceuticals Announces Commercial Availability of PEDMARK® (sodium thiosulfate injection) in the United States

~ PEDMARK is the First and Only FDA-Approved Therapy Indicated to Reduce the Risk of Cisplatin-Induced Hearing Loss in Pediatric Patients ~ ~ Fennec...

FENC Twits

Here you can normally see the latest stock twits on FENC, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example